tiprankstipranks
Blurbs

Aptose Biosciences (APTO) Gets a Buy Rating from RBC Capital

RBC Capital analyst Gregory Renza maintained a Buy rating on Aptose Biosciences (APTOResearch Report) on March 22 and set a price target of $7.00. The company’s shares closed last Wednesday at $1.22, close to its 52-week low of $1.00.

According to TipRanks.com, Renza is a 1-star analyst with an average return of -2.0% and a 40.0% success rate. Renza covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Verrica Pharmaceuticals, and Pacira Pharmaceuticals.

Aptose Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $7.73, implying a 549.6% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a C$12.00 price target.

See the top stocks recommended by analysts >>

Based on Aptose Biosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $11.33 million. In comparison, last year the company had a GAAP net loss of $13.25 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.

Read More on APTO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More